T2DM in children

Definition and Epidemiology

• Type 2 diabetes mellitus (T2DM), formerly known as adult-onset or non-insulin-dependent diabetes, is a heterogeneous metabolic disorder characterized by peripheral insulin resistance coupled with a progressive failure of the pancreatic beta cells to produce adequate insulin to meet metabolic demands.
• Unlike patients with Type 1 Diabetes Mellitus (T1DM) who have an absolute deficiency of insulin, patients with T2DM exhibit a relative insulin deficiency and typically do not require exogenous insulin for survival, at least in the early stages of the disease.
• While historically considered a disease of adults, the dramatic global rise in childhood obesity over the past few decades has led to a markedly increased incidence of T2DM in the pediatric and adolescent populations.
• T2DM currently accounts for 10% to 50% of all newly diagnosed cases of diabetes in adolescents, depending heavily on the ethnic population being served.
• The prevalence of T2DM in youth (aged 10-19 years) surged from 34 cases per 100,000 in 2001 to 67 cases per 100,000 in 2017 in the United States.
• There is a pronounced ethnic predilection; T2DM in children is diagnosed at significantly higher rates among Native American, Hispanic American, Black American, Pacific Islander, and Asian youth compared to White youth.
• The onset of pediatric T2DM typically occurs during the teenage years, corresponding with the physiological insulin resistance associated with the pubertal growth spurt, and is rarely diagnosed before 10 years of age.
• Females are more commonly affected than males, with a male-to-female ratio of approximately 1:1.5 to 1:2.

Etiology and Pathogenesis

Genetic and Epigenetic Factors

• T2DM is a highly polygenic disease, strongly aggravated by environmental and lifestyle factors.
• The disease possesses a powerful heritable component; a family history of T2DM in a first- or second-degree relative is present in 75% to 90% of affected youth.
• Low birthweight and intrauterine growth restriction (IUGR) are significantly associated with an increased risk of developing T2DM later in life.
• This relationship forms the basis of the "thrifty phenotype hypothesis," which postulates that poor fetal nutrition epigenetically programs the fetus to maximize nutrient storage, rendering the child highly susceptible to rapid weight gain, obesity, and insulin resistance when exposed to a post-natal environment of caloric abundance.
• Conversely, maternal gestational diabetes and fetal macrosomia also predispose offspring to childhood obesity and T2DM, indicating that both extremes of the intrauterine nutritional environment exert detrimental epigenetic effects.

Pathophysiology of Insulin Resistance and Beta-Cell Failure

• The fundamental driver of T2DM is obesity, specifically central or visceral adiposity, which induces profound peripheral insulin resistance at the level of skeletal muscle, liver, and adipose tissue.
• Adipose tissue functions as an active endocrine organ. Visceral obesity alters lipid partitioning and leads to the accumulation of ectopic fat in the liver (hepatic steatosis) and skeletal muscle (intramyocellular lipids), which directly impairs insulin signaling pathways.
• Insulin resistance is exacerbated by the release of free fatty acids (FFAs) and pro-inflammatory cytokines (such as Interleukin-6 and Tumor Necrosis Factor-alpha) from hypertrophied adipocytes, alongside a reduction in adiponectin, an anti-atherogenic and insulin-sensitizing adipocytokine.
• Initially, the pancreatic beta cells compensate for this peripheral insulin resistance by increasing insulin secretion (hyperinsulinemia).
• Overt T2DM develops when the beta cells eventually fail and can no longer secrete sufficient insulin to overcome the peripheral resistance.
• A critical distinction between adult-onset and childhood-onset T2DM is that youth exhibit a much more rapid and aggressive decline in beta-cell function and insulin secretory capacity compared to adults.
• Glucotoxicity (chronic hyperglycemia) and lipotoxicity (chronic elevation of free fatty acids) further damage the beta cells, creating a vicious cycle that accelerates beta-cell apoptosis and functional failure.

Environmental and Lifestyle Factors

• The epidemic of pediatric T2DM is inextricably linked to lifestyle factors, particularly the consumption of high-calorie, high-fat, and high-glycemic-index foods (e.g., sugar-sweetened beverages, excessive fruit juice), coupled with a profound decrease in physical activity and increased sedentary screen time.
• Maternal smoking during pregnancy independently increases the risk of obesity and T2DM in the offspring.
• Exposure to environmental endocrine disruptors, such as certain land and air pollutants, which are lipophilic and stored in adipose tissue, has been implicated in promoting insulin resistance.
• Psychosocial stress, sleep deprivation, and the use of certain medications, particularly atypical antipsychotics (e.g., olanzapine) and tricyclic antidepressants, strongly promote weight gain and can directly induce beta-cell dysfunction and insulin resistance.

Clinical Features

• The clinical presentation of T2DM in children is often insidious and spans a broad spectrum of severity.
• Many patients are entirely asymptomatic for months or years, with the diagnosis made incidentally via the discovery of glycosuria during a routine physical examination or through targeted screening of high-risk obese youth.
• When symptomatic, children may present with mild to moderate classic manifestations of hyperglycemia, including polyuria, polydipsia, and nocturia.
• Unlike T1DM, a history of severe, rapid weight loss is less common; instead, patients frequently seek medical attention due to excessive, continuous weight gain and chronic fatigue.
• Over 90% of children diagnosed with T2DM are overweight or obese, with a body mass index (BMI) typically exceeding the 85th or 95th percentile for age and sex.
• Acanthosis nigricans, a dark, velvety hyperpigmentation of the skin primarily found in flexural areas (nape of the neck, axillae, groin), is a robust clinical hallmark of severe hyperinsulinemia and insulin resistance, and is present in approximately 86% to 90% of affected youth.
• Despite T2DM traditionally being considered a non-ketotic condition, approximately 5% to 25% of adolescents with T2DM present acutely in Diabetic Ketoacidosis (DKA) at the time of diagnosis, often complicating the initial differentiation from T1DM.
• A Hyperglycemic Hyperosmolar State (HHS), characterized by extreme hyperglycemia, profound dehydration, and altered mental status without significant ketoacidosis, is a rare (approx. 2%) but highly lethal presentation of pediatric T2DM that carries a significantly higher mortality rate than DKA.

Diagnostic Criteria and Screening

Diagnostic Criteria

• The biochemical criteria for diagnosing T2DM in children are identical to those used for adults and for T1DM.
• A fasting plasma glucose level of $\ge$ 126 mg/dL (7.0 mmol/L), following an overnight fast of at least 8 hours.
• A 2-hour postprandial plasma glucose level of $\ge$ 200 mg/dL (11.1 mmol/L) during a standard oral glucose tolerance test (OGTT) utilizing a glucose load of 1.75 g/kg (maximum 75 g).
• A random plasma glucose level of $\ge$ 200 mg/dL (11.1 mmol/L) in a patient exhibiting classic symptoms of hyperglycemia (polyuria, polydipsia, weight loss).
• A Hemoglobin A1c (HbA1c) level of $\ge$ 6.5% (48 mmol/mol).
• Prediabetes (dysglycemia) is defined by impaired fasting glucose (100-125 mg/dL), impaired glucose tolerance (2-hour OGTT plasma glucose 140-199 mg/dL), or an HbA1c between 5.7% and 6.4%.

Screening Guidelines for High-Risk Youth

• Because the onset of T2DM is insidious and prolonged asymptomatic hyperglycemia causes silent microvascular damage, active screening is mandated for high-risk pediatric populations.
• Screening should be initiated at 10 years of age, or at the onset of puberty if it occurs earlier.
• The primary criterion for screening is a child who is overweight or obese (BMI > 85th percentile for age and sex).
• In addition to being overweight, the child must possess one or more of the following risk factors:
  • A family history of T2DM in a first- or second-degree relative.
  • A maternal history of diabetes or gestational diabetes during the child's gestation.
  • Belonging to a high-risk racial or ethnic group (Native American, Black American, Hispanic, Asian/Pacific Islander).
  • Clinical signs of insulin resistance or associated conditions (e.g., acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight).
• The recommended screening tests include fasting plasma glucose, HbA1c, or an OGTT. If the initial screening is normal, testing should be repeated every 1 to 2 years based on clinical suspicion and risk trajectory.

Differentiating Type 2 from Type 1 Diabetes

• Differentiating T2DM from T1DM is crucial for guiding appropriate therapy, though it can be challenging as the phenotypes increasingly overlap (e.g., the rising prevalence of obesity in children with T1DM).
• Serum C-peptide levels, a surrogate marker of endogenous insulin production, are typically low or undetectable in T1DM, but are normal or significantly elevated in early T2DM due to compensatory hyperinsulinemia.
• Pancreatic islet autoantibodies (e.g., GAD, ICA, IAA, IA-2A, ZnT8A) are the hallmark of T1DM and are negative in classic T2DM.
• However, up to 10% to 30% of obese adolescents presenting with a classic T2DM phenotype (including acanthosis nigricans and preserved C-peptide) may test positive for one or more islet autoantibodies. This phenomenon is sometimes referred to as "Double Diabetes" or Latent Autoimmune Diabetes in Youth, suggesting a superimposed autoimmune destruction on an insulin-resistant background.
• Conversely, children presenting with a clinical picture of T2DM but lacking severe obesity, lacking a strong family history, or presenting before 10 years of age should undergo genetic testing to rule out Maturity-Onset Diabetes of the Young (MODY), particularly if autoantibodies are negative.

Complications and Comorbidities

Microvascular and Macrovascular Complications

• A critical defining feature of youth-onset T2DM is the highly accelerated tempo of microvascular and macrovascular complications compared to both adult-onset T2DM and youth-onset T1DM.
• Data from the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study revealed a rapid and relentless progression of cardiovascular risk factors within just a few years of diagnosis, despite active treatment.
• Diabetic Nephropathy progresses aggressively; microalbuminuria is present in approximately 6% of patients at diagnosis, rapidly increasing to 17% within 3 years. End-stage renal disease can manifest as early as 10 years post-diagnosis.
• Diabetic Retinopathy also develops earlier and at higher rates in youth-onset T2DM compared to T1DM, with early structural vascular abnormalities frequently detectable shortly after diagnosis.
• Peripheral Neuropathy demonstrates a significantly higher prevalence in youth with T2DM (approx. 25.7%) compared to those with T1DM (approx. 8.2%).
• Macrovascular disease precursors, such as endothelial dysfunction, increased arterial stiffness, and increased carotid intima-media thickness, are prominent in adolescents with T2DM, significantly elevating their lifetime risk for premature stroke and myocardial infarction.

Associated Comorbidities

• Because T2DM in youth is driven by severe obesity and insulin resistance, patients frequently present with an array of established comorbidities at the time of diabetes diagnosis.
• Hypertension is remarkably common, affecting up to 70% of youth with T2DM, and frequently requires early pharmacological intervention.
• Dyslipidemia is nearly universal, characteristically presenting with elevated serum triglycerides and suppressed high-density lipoprotein (HDL) cholesterol, alongside elevated low-density lipoprotein (LDL) cholesterol.
• Non-Alcoholic Fatty Liver Disease (NAFLD) is highly prevalent due to ectopic lipid deposition. It may manifest with mild elevations in alanine aminotransferase (ALT) and hepatomegaly, and can progress to non-alcoholic steatohepatitis (NASH) and hepatic fibrosis.
• Polycystic Ovary Syndrome (PCOS) frequently co-occurs in female patients, characterized by hyperandrogenism (hirsutism, severe acne), oligomenorrhea, and anovulatory infertility, further exacerbating the underlying insulin resistance.
• Obstructive Sleep Apnea (OSA) is strongly associated with severe obesity and contributes to systemic inflammation, worsening insulin resistance, and profound endothelial dysfunction.

Management and Treatment

Lifestyle Interventions

• The foundational cornerstone of management for all youth with T2DM is rigorous, intensive lifestyle modification.
• Medical Nutrition Therapy requires consultation with a skilled pediatric dietitian. The focus is on a structured, low-glycemic-load diet that eliminates sugar-sweetened beverages (sodas, juices), reduces saturated fats and trans-fats, and strictly controls portion sizes to induce a negative energy balance.
• Physical Activity must be substantially increased. Guidelines recommend a minimum of 60 minutes of moderate-to-vigorous aerobic exercise daily, accompanied by muscle- and bone-strengthening activities at least three days per week.
• Sedentary behaviors and non-academic screen time must be rigidly curtailed to less than 2 hours per day.
• Despite its theoretical importance, long-term adherence to lifestyle modification is notoriously poor in the adolescent population; the TODAY study demonstrated that lifestyle interventions alone, or even in combination with pharmacotherapy, frequently fail to halt the progressive decline of beta-cell function in the "real world" setting.

Pharmacological Therapy

• Metformin remains the first-line oral pharmacological agent for youth-onset T2DM and is FDA-approved for children 10 years of age and older.
• Mechanism of Action: Metformin primarily acts by decreasing hepatic glucose production (gluconeogenesis) and significantly improving peripheral insulin sensitivity in skeletal muscle.
• Dosing: Therapy is typically initiated at a low dose of 500 mg daily and gradually titrated over several weeks to a maximum therapeutic dose of 1000 mg twice daily (2000 mg/day).
• Side Effects: The most common adverse effects are gastrointestinal (nausea, bloating, flatulence, diarrhea), which are usually transient and mitigated by slow titration and administration with meals.
• Liraglutide is a Glucagon-Like Peptide-1 (GLP-1) receptor agonist that is administered via subcutaneous injection and is approved as a second-line adjunct therapy for children 10 years and older who fail to achieve glycemic targets on metformin alone.
• Liraglutide offers the dual benefit of stimulating glucose-dependent insulin secretion while concurrently promoting early satiety, delaying gastric emptying, and inducing highly desirable weight loss.
• The starting dose of Liraglutide is 0.6 mg daily, titrated weekly to a maximum of 1.8 mg daily. It is strictly contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN 2).

Insulin Therapy

• Exogenous insulin therapy is absolutely indicated at presentation for patients who exhibit severe metabolic decompensation, defined by the presence of DKA, HHS, marked classic symptoms (polyuria, significant weight loss), or an initial HbA1c > 8.5%.
• The primary goal of initial insulin therapy is to rapidly reverse severe glucotoxicity and lipotoxicity, which temporarily paralyze endogenous beta-cell function.
• Typically, a long-acting basal insulin analog (e.g., glargine) is initiated at a dose of 0.5 units/kg/day.
• Once metabolic stability is achieved, symptoms resolve, and endogenous beta-cell insulin secretion recovers, many youth can be successfully weaned off exogenous insulin and transitioned to metformin monotherapy.
• If HbA1c targets (<7.0%) cannot be maintained on maximum doses of metformin and GLP-1 agonists, the permanent addition of basal insulin, and eventually a full basal-bolus multiple daily injection regimen, becomes necessary as the disease relentlessly progresses.

Management of Comorbidities

• Because microvascular and macrovascular complications progress rapidly in pediatric T2DM, aggressive surveillance and pharmacological management of comorbidities are mandatory from the time of diagnosis.
• Hypertension: Blood pressure persistently >90th percentile for age, sex, and height demands lifestyle intervention. If it exceeds the 95th percentile, pharmacological therapy with Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin Receptor Blockers (ARBs) is indicated, as these agents concurrently offer renal protection.
• Dyslipidemia: The therapeutic target is an LDL cholesterol < 100 mg/dL. If strict dietary modification fails to lower LDL below 130 mg/dL, the initiation of Statin therapy is highly recommended.
• Diabetic Nephropathy: The presence of persistent microalbuminuria (urine albumin-to-creatinine ratio >30 mg/g) necessitates immediate treatment with an ACE inhibitor or ARB to delay progression to overt renal failure.

Bariatric Surgery

• Given the high failure rates of medical and lifestyle therapies in arresting the progression of severe youth-onset T2DM, metabolic bariatric surgery is increasingly recognized as a potent therapeutic tool.
• Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy have demonstrated exceptional efficacy in achieving durable weight loss, reversing severe insulin resistance, and inducing long-term, complete remission of T2DM in adolescents.
• Bariatric surgery is currently recommended for adolescents who have attained their final adult height, possess a BMI $\ge$ 35 kg/m2 (or 120% of the 95th percentile), and suffer from severe, clinically significant comorbidities such as poorly controlled T2DM, severe OSA, or advanced NAFLD/NASH.